Delta-Fly Pharma, Inc. (TYO:4598)

Delta-Fly Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	-	-	-	300	300
Revenue Growth (YoY)	-	-	-	-	-	200.00%
Gross Profit	-	-	-	-	300	300
Selling, General & Admin	213	212	229	261	287	253
Research & Development	1,377	1,437	1,118	1,011	940	866
Other Operating Expenses	59	59	56	43	34	33
Operating Expenses	1,649	1,708	1,403	1,315	1,261	1,152
Operating Income	-1,649	-1,708	-1,403	-1,315	-961	-852
Currency Exchange Gain (Loss)	1	-1	-5	-5	-	-3
Other Non Operating Income (Expenses)	-12	-10	-19	-5	-3	-4
Pretax Income	-1,660	-1,719	-1,427	-1,325	-964	-859
Income Tax Expense	2	2	2	3	3	3
Net Income	-1,662	-1,721	-1,429	-1,328	-967	-862
Net Income to Common	-1,662	-1,721	-1,429	-1,328	-967	-862
Shares Outstanding (Basic)	11	9	7	6	5	5
Shares Outstanding (Diluted)	11	9	7	6	5	5
Shares Change (YoY)	29.12%	22.38%	26.91%	4.61%	17.64%	3.08%
EPS (Basic)	-152.73	-195.56	-198.72	-234.37	-178.52	-187.22
EPS (Diluted)	-152.73	-195.56	-198.72	-234.37	-178.52	-187.22
Free Cash Flow	-	-1,834	-1,280	-1,303	-940	-726
Free Cash Flow Per Share	-	-208.41	-178.00	-229.96	-173.54	-157.68
Gross Margin	-	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-	-320.33%	-284.00%
Profit Margin	-	-	-	-	-322.33%	-287.33%
Free Cash Flow Margin	-	-	-	-	-313.33%	-242.00%
EBITDA	-1,648	-1,707	-1,402	-1,314	-960	-850
EBITDA Margin	-	-	-	-	-	-283.33%
D&A For EBITDA	1	1	1	1	1	2
EBIT	-1,649	-1,708	-1,403	-1,315	-961	-852
EBIT Margin	-	-	-	-	-	-284.00%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.